H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Promising Clinical Data and Strategic Expansion Justify Buy Rating for Coherus Biosciences
Coherus BioSciences Price Target Cut to $1.05/Share From $1.50 by UBS
Coherus BioSciences Is Maintained at Neutral by UBS
Coherus BioSciences Analyst Ratings
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
TD Cowen Maintains Coherus BioSciences(CHRS.US) With Buy Rating
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Truist Financial Sticks to Their Buy Rating for Coherus Biosciences (CHRS)
Coherus BioSciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Coherus Biosciences: Promising Phase 2 Data and Strategic Valuation Drive Buy Rating
TD Cowen Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)
Coherus BioSciences Price Target Raised to $6.00/Share From $4.00 by Baird
Coherus BioSciences Is Maintained at Outperform by Baird
Coherus BioSciences Analyst Ratings